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Preventing episodic migraine with caloric vestibular stimulation: a randomized controlled trial 
Abstract.  
Objective: To evaluate the safety and efficacy of a novel solid-state, caloric vestibular stimulation (CVS) 
device to provide adjuvant therapy for the prevention of episodic migraine in adult migraineurs. 
Background:  Migraine causes significant disability in ~12% of the world population.   No current 
migraine preventive treatment provides full clinical relief, and many exhibit high rates of discontinuation 
due to adverse events.  Thus, new therapeutic options are needed.  CVS may be an effective and safe 
adjuvant-therapy for the prevention of episodic migraine.  
Methods:  In a multicenter, parallel-arm, block-randomized, placebo-controlled clinical trial 
(clinicaltrials.gov: NCT01899040), subjects completed a 3-month treatment with the TNMª device for 
CVS (refer to Figure 2 for patient enrollment and allocation). The primary endpoint was the change in 
monthly migraine days from baseline to the third treatment month.  Secondary endpoints were 50% 
responder rates, change in prescription analgesic usage and difference in total subjective headache-related 
pain scores.  Device safety assessments included evaluation of any impact on mood, cognition or balance. 
Results:  Per-protocol, active-arm subjects showed immediate and steady declines in migraine frequency 
over the treatment period.  After three months of treatment, active-arm subjects exhibited significantly 
fewer migraine days (-3.8 ± 0.5 from a baseline burden of 7.7 ± 0.5 migraine days).  These improvements 
were significantly greater than those observed in  control subjects (-1.1 ± 0.6 from a baseline burden = 6.9 
± 0.7 migraine days) and represented a therapeutic gain of -2.7 migraine days, CI = -0.9 to -4.7, p = 0.012.  
Active arm subjects also reported greater reductions in acute medication usage and monthly pain scores 
compared to controls.  No adverse effects on mood, cognition or balance were reported. Subjects completed 
the trial with an average rate of 90% treatment adherence.  No serious or unexpected adverse events were 
recorded.  The rate of expected adverse events was similar across the active and the placebo groups, and 
evaluation confirmed that subject blinding remained intact. 
Conclusion:  The TNMª device for CVS appears to provide a clinically efficacious and highly tolerable 
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Migraine is a common and disabling disorder afflicting approximately 12% of the population 
worldwide
1
.   Migraine attacks often result in significant impairment and loss of ability to function.  They 
create enormous financial burden with approximately one billion dollars spent in healthcare utilization as 
well as thirteen billion dollars lost in productivity annually in the United States alone
2
.   Despite 
widespread use of medical intervention for the acute treatment of migraine attacks (approximately 98% of 
patients report using an over-the-counter medication, prescribed medication, or a combination thereof)
3
, 
patients are largely resistant to the use of prophylactic treatments.  Indeed, of the estimated 38% of 
migraineurs likely to benefit, only 13% currently use migraine prophylactics
4
.    Reasons for limited use of 
prophylactics include unpleasant side effects, cost, and perceived low efficacy of the currently available 
medications and other therapies
5, 6
.  Thus, a significant need for new, efficacious and more tolerable 
therapies exists. 
Here we sought to establish the safety and efficacy of caloric vestibular stimulation (CVS) treatment 
using a novel, solid-state device (TNMª, Scion Neurostim, LLC) for the prevention of episodic migraine.  
CVS is a widespread clinical tool used both to diagnose balance disorders and to confirm the absence of 
brainstem function.  Historically, water or air irrigators have been used to warm or cool the external 
auditory canal. Both warming and cooling temperature changes create convection currents in the 
endolymphatic fluid of the horizontal semicircular canal.  These currents cause cupular deflection which 
alters the tonic firing rate of the vestibular nerves and, in turn, elicits broad autonomic responses, including 






therapeutic potential has been hindered by the unpleasant side-effects, thermal imprecision, lack of dose 
control and administration complexity of standard water and air irrigation methods
7
, impediments that were 
overcome with the development of a solid-state device for delivering CVS
8
.  The potential for CVS to 
provide effective prophylaxis for episodic migraine is supported by several findings.  
First, while the precise pathology underlying migraine remains largely unknown and the neural circuits 
involved are wide-spread, results from a number of neuroimaging studies consistently suggest that migraine 
is a neurological disorder involving brainstem dysfunction
9-11
.  This hypothesis is relevant because the 
brainstem is among the many neural regions activated by CVS
12, 13
, a set of strong pathways corroborated 
by the well-established diagnostic sensitivity of CVS to brainstem dysfunction.  Although neuroimaging 
data evaluating the precise patterns of brainstem activation by CVS have been limited due to the difficulty 
of achieving anatomic resolution with these techniques, anatomical tracing studies have demonstrated 
dense and often reciprocal connections between the vestibular nuclei, located within the pons and medulla, 
and other brainstem regions implicated in migraine --  including the periaqueductal gray, the parabrachial 
nucleus, the locus coeruleus, the reticular formation, the dorsal spinal and mesencephalic trigeminal nuclei 
and the dorsal raphe nuclei
14-16
 (depicted in Figure 1C).  Furthermore, recent transcranial Doppler 
sonography data demonstrate that CVS treatment with the device elicits changes in cerebrovascular 
dynamics that point to brainstem neuromodulation
8
. Second, irrigation calorics have been shown, albeit in 
small, uncontrolled samples, to acutely mitigate pain, including pain experienced during migraine attacks
17-
19
.   
Based on the above findings, we gathered preliminary clinical evidence for CVS-mediated prevention of 
episodic migraine by conducting a three-subject pilot study that assessed the feasibility and safety of 
longitudinal CVS treatment in the home setting.  All three episodic migraineurs demonstrated reduced 
headache frequency after six weeks of CVS therapy
8
. Notably, all subjects demonstrated excellent 
treatment adherence, and no adverse events were reported.  To further assess the efficacy and safety of the 
caloric vestibular stimulation device
8
 developed by Scion NeuroStim, LLC, for the prevention of episodic 
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migraine, we then conducted a prospectively powered, randomized, placebo-controlled clinical trial 
(NCT01899040; www.clinicaltrials.gov).  The results are described herein. 
 
II. METHODS 
A multicenter, parallel-arm, block-randomized, double-blinded, placebo-controlled clinical trial was 
conducted to determine the superiority of CVS therapy over placebo treatment.  Subjects were randomized 
in a 1: 1 ratio.  Both per- protocol (PP) and intention-to-treat (ITT) data were analyzed.  The study was 
conducted across five centers in the United States and one in the United Kingdom (see Supplemental Table 
1). 
 
Standard protocol approval and informed consent.  In 2013, the device was designated by the U.S. 
Food and Drug Administration as nonsignificant risk (NSR) for a study of episodic migraine.!!This study 
was approved by the appropriate institutional review board for each participating center.  The research 
coordinator for each study site evaluated eligibility, obtained informed consent and enrolled the participants 
in the study. Written informed consent was obtained from all participants. 
 
Subjects and medication usage.  Subjects fulfilling the following criteria were included in the study: 
18-65 years old, a diagnosis of episodic migraine without aura according to the International Headache 
Classification of Headache Disorders-II guidelines
20, 21
 at least six months prior to entering the study, a 
stable history of 4-14 migraine headache days per month for the three months preceding the study, and no 
evidence of a balance disorder according to a Berg Balance Scale assessment
22
.  Exclusion criteria were 
failure to respond to more than two classes of properly administered migraine prophylactic pharmaceutical 
therapies, an inability to reliably use the device or to complete the daily headache diary, pregnancy, night 
shift work, history of cardiovascular disease, prior diagnosis of vestibular migraine
21





 or post-traumatic migraine, history of unstable mood or anxiety disorders, use of hearing aids or 
cochlear implants, chronic tinnitus, temporomandibular joint disease, history of traumatic brain injury, 
comorbidity with another neurological disease other than headaches, a diagnosis of vestibular dysfunction, 
abuse of drugs or alcohol, current experience with medication overuse headaches, eye surgery within three 
months or ear surgery within six months of the study, active ear infections or perforated tympanic 
membrane, participation in another clinical trial within 30 days of the trial and use of Botox treatments for 
migraines.  Additionally, subjects who were taking migraine prophylactics were originally excluded from 
the study.  However, because prophylactic treatment is consistent with standards of practice in headache 
clinics, the protocol was later modified to include these subjects.  See Supplemental Appendix 2 for details 
relating to these changes.  Subjects were allowed to use abortive medications for the symptomatic relief of 
migraine as well as pharmaceutical prophylactics provided there were no changes (type or dosage) during 
the course of the study or the three months immediately preceding.   Subjects were withdrawn from the 
study if they exhibited more than 14 headache days during the one-month baseline (BL) period, withdrew 
consent, demonstrated significant non-adherence (investigator-determined) or met the exclusion criteria any 
time during the study.  
 
Study design, subject randomization and blinding.  Eligible subjects entered a 28-day pre-treatment 
baseline period during which they completed electronic daily headache diaries recording headache 
occurrence.  If a headache occurred, subjects also logged (i) headache duration, (ii) severity on a 11-point 
visual analog scale (with 0 indicating no pain and 10 indicating worst possible pain)
23
, (iii) whether they 
considered the headache to be a migraine, (iv) any migraine-associated symptoms experienced (including 
nausea and/or vomiting, dizziness and sensitivities to light, sound and smells) (v) qualities related to 
headache pain (i.e., unilaterality, pulsating quality, and prevention and/or worsening with physical activity) 
as well as (vi) the dose / type of abortive medication taken.  The form used for the daily headache diary can 
be found in the complete study protocol provided in Supplemental Appendix 1. The scores from (ii) were 
6 
 
summed to provide a total monthly headache pain score.  In accordance with the standard of care for most 
headache clinics in the United States which encourages appropriate use of migraine abortive medication, a 
migraine day was defined as any day when the subject considered his/her headache to be a migraine.  All 
patients received training for filling out the daily headache diaries. Electronic diary entries were collected 
using validated REDCap electronic data capture tools hosted at Duke University
24
. 
Diary compliant subjects who satisfied the inclusion/exclusion criteria were randomized into active or 
placebo groups.   Block randomization was followed to ensure that patients and investigators were blinded 
to treatment allocation.  Each site received packets of four well-shuffled envelopes containing two active 
and two placebo cards.  Sealed envelopes were opened by the unblinded coordinator who then inserted the 
appropriate SD card (either active or placebo) and logged the coded treatment arm for each subject, thereby 
protecting against inadvertent or inappropriate access to treatment assignment. The unblinded study site 
coordinator was the only individual on-site with access to the allocation information.  Information about 
treatment arm allocation was not shared with the subjects, investigators, data technicians or the statisticians.  
Sites were instructed to complete a packet before opening a new packet.  In the informed consent, subjects 
were made aware of the existence of a placebo arm, but the topic was not further discussed.  Subjects were 
not told that CVS was the active therapy.  In the Informed Consent the device was described as a brainstem 
neuromodulator.  
On treatment day one, subjects returned to the clinic where they completed a battery of tests to assess 
baseline mood and cognition.  These tests included the Beck Depression Inventory-II (BDI-II)
25
, a 
subjective rating scale of depression, the Beck Anxiety Inventory (BAI)
26
, a subjective rating scale of 
anxiety, the Digit-Symbol coding test
27
 to assess sequence processing speed, the Everyday Cognition rating 
scale - 20
28
 to assess perceived cognition in daily life, Trail Making Tests A to assess speed processing and 
Trail Making Test B to asses complex sequencing with set-shifting
29
, the Controlled Oral Word Association 
test
30
 to assess verbal fluency and a short term memory test
31
.   
The unblinded study site coordinator then administered the first treatment and trained subjects to self-
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administer treatments.   
CVS treatments.  Subjects self-administered treatments twice daily for three months (84 days) and were 
instructed to separate daily treatments by at least one hour. The CVS device provided patient-lockouts 
which limited subjects to two prescribed treatments per day.  To maximize the thermoconvective effect of 
CVS
32
, subjects were instructed to lie supine on a ~22¡ wedge pillow for treatments (Figure 1A).  Placebo 
and active CVS treatments were delivered via a headset, fashioned like music earphones, with two 
independently-controlled thermoelectric devices attached to aluminum earpieces which fit inside the ear 
canal and abut but do not enter the bony canal
8
. 
  For active treatment, a time-varying saw-tooth waveform (shown in Figure 1B) was delivered.  After 
each two-day period, the ears receiving the warm and cold waveforms were switched in order to mitigate 
the hypothetical risk of unintentionally creating a baseline vestibular asymmetry after the treatment period.  
There were two placebo conditions during the course of this study.  The first placebo was designed to bring 
both earpieces to 37¡ C and maintain that constant temperature for approximately four minutes.  However, 
due to the thermistor sensitivity (+/- 2¡ C), there was a slight divergence between the intended and actual 
temperature of the earpieces (i.e., an overshoot followed by small oscillations as the temperature tracking 
settled at the set point of 37¡ C).  While we expected these small fluctuations to be negligible, three of 20 
subjects in this placebo condition exhibited slight dizziness and/or nausea that was likely to be due to active 
treatment, as determined by the blinded clinicians (see Table 3).  Further concern over the validity of the 
initial placebo was raised by a published report demonstrating that temperature differences as little as 1¡ C 
away from body temperature are sufficient to evoke vestibular responses
33
.  Therefore, to minimize 
vestibular stimulation of unknown magnitude in the placebo condition, the study was paused, and the 
following changes were made to create a new inactive placebo condition: 1) earpieces remained unpowered 
(though the headset fans continued to function), and 2) an ethylene-vinyl copolymer cap was added to the 
earpieces to minimize the cooling effect of the bare aluminum during the initial headset placement.  
Changes were approved by all internal review boards, and the U.S. Food and Drug Administration was 
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notified of the protocol and design changes.  See Supplemental Figure 1 for actual temperatures recorded 
by the thermistors during the two placebo conditions and Supplemental Appendix 3 for complete details 
relating to the change in the placebo condition.  There were no changes to the active arm protocol during 
the course of the study.  As such, the measures of efficacy from all active arm subjects were combined and 
compared to the new inactive placebo condition (referred to hereafter as Òthe placeboÓ).  Although data 
from the first partially active placebo condition were not included in the primary analysis of efficacy, data 
from these subjects were still evaluated to assess device safety and usability; and evaluation of the primary 
endpoint including the data from these subjects is provided in Supplemental Figure 2   This group will be 
referred to hereafter as Òthe partially active placeboÓ group.  There was no interim analysis of efficacy 
during the course of the study. 
Treatment times and dates were recorded by the device control unit and were analyzed to assess 
treatment adherence.  Subjects returned to the clinic after two weeks of home treatments and at the end of 
the three-month treatment period.  At these times, balance was re-assessed using the Berg balance scale, 
and subjects completed questionnaires about the usability of the device.  Additionally, subjects were 
assessed for changes in mood and cognition using the same battery of tests used at the first treatment visit.  
To assess potential effects on long-term memory, at the final visit subjects were asked to identify faces they 
had seen previously (during their first short-term memory exam).   
Every two weeks during either clinic visits or phone calls with site coordinators and daily in their 
headache diaries, subjects were asked whether they experienced any adverse events (AEs). 
  
Outcome measures.  The change in the average number of monthly migraine days between the baseline 
period and the third treatment month served as the primary efficacy endpoint.  Secondary efficacy measures 
were also analyzed and included: 1) the percentage of subjects having at least 50% reduction of monthly 
migraine days between the baseline and the third treatment month, 2) the change in the total monthly 
headache pain scores (a novel measure designed for this study) and 3) the change in monthly acute abortive 
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prescribed migraine medication taken.  Changes in mood/cognition were intended to be a secondary 
endpoint; however, due to a lack of baseline dysfunction across randomized subjects, they were instead 
assessed to establish device safety.   To assess blinding efficacy, on their final visit subjects were asked to 
guess their treatment allocation and provide the reasons for their guess.  Inclusion in the PP analysis of 
headache-related endpoints required treatment adherence   IRU HDFK WUHDWPHQW PRQWK DQG KHDGDFKH
diary adherence for at least 25 days during the baseline and the third treatment month (28 days each).  
Diary adherence for at least 25 the 28 day period was required to accurately assess efficacy from our 
primary and secondary endpoints.  Inclusion in the ITT analysis of efficacy in this study only required 
headache diary adherence.  Subjects that did not meet the criterion for diary adherence were not included in 
the analysis for efficacy but were included in the measures of safety and treatment adherence.  Because 
diary adherence was not essential to accurately assess mood and cognitive effects of CVS treatment, 
treatment adherence was the only requirement for inclusion in the PP analysis of mood and cognition. 
Statistical analysis.  Trial cohort size was chosen based on the need to demonstrate safety and by 
considering the designs of previous device studies
34, 35
.  Given the lack of a priori outcome data from 
which to perform a power estimate for the primary endpoint, a power analysis was conducted on a binary 
outcome of the 50% responder rate (a secondary endpoint) for a range of assumed efficacy values.  Based 
on previous studies, it was estimated that 15% of placebo arm subjecWVZRXOG H[KLELW D UHVSRQVH
rate
34, 35 2QWKDWEDVLVVXEMHFWVZRXOGSURYLGHSRZHUWRGHWHFWDVLJQLILFDQWGLIIHUHQFH LQWKLV
measure (alpha < 0.05), assuming a 50% response rate in 45% of active arm subjects, and would 
sufficiently demonstrate device safety. 
Change scores described in this study are differences in measures between the baseline and the third 
treatment month unless otherwise specified. Distributions of the primary and secondary endpoints were 
examined for normality to determine the appropriate statistical tests to use in the analysis. Statistical 
significance for the primary outcome was determined using Mann-Whitney U-tests.  The changes in 
monthly migraine days between the baseline month and the third treatment month within each group were 
10 
 
evaluated using Wilcoxon matched-pairs signed rank tests.  Statistical significance for the differences in the 
QXPEHURI VXEMHFWVGHPRQVWUDWLQJ UHVSRQVH UDWH, the ratio of male versus female subjects and the 
accuracy of the allocation guesses were evaluated using two-sided chi-square tests.  The percent-change in 
migraine days was also evaluated as an ordinal variable using a Mann-Whitney U test.  The changes in total 
monthly headache pain scores and monthly acute anti-migraine prescription medication taken (secondary 
endpoints), as well as the differences in baseline demographics of age, education, and disease duration were 
compared using unpaired studentÕs t-tests.  Within-group changes for the secondary outcome measures 
were evaluated using paired studentÕs t-tests.  Only subjects with current prescriptions for acute anti-
migraine medications were included in the secondary endpoint analysis evaluating medication usage.  
Statistical significance for all assessments of mood and cognition were evaluated using paired studentÕs t-
tests for within group effects and unpaired studentÕs t-tests for between group effects. Secondary endpoints 
were assessed without adjustment for multiple tests.  No stratification variables were used in the analysis.  
Decisions to conduct sub-analyses with respect to the change in migraine days within the PP group that 
guessed active allocation and within the PP group that did not comment on treatment-related sensory 
experience as reason for their allocation guess were made upon examination of the allocation guessing chi-
square results.  Likewise, the decision to evaluate the percentage reduction as a continuous variable was 
made after evaluating the chi-VTXDUHDQDO\VLVRIWKHUHVSRQGHUUDWHOutcomes of repeated measures 
were analyzed using linear mixed models.  The linear mixed models were fit to examine the change in 
migraine days over the treatment period. The models included time, treatment group and treatment group 
by time interaction. The association among repeated measures was assumed to follow a compound 
symmetry variance-covariance structure.  No data transformations were required to fit the models.  
Significance of each of the variables in the model was assessed at alpha = 0.05.  Data are presented as mean 
± standard error of the mean unless otherwise noted.  Analysis was performed using SAS 9.4 (SAS 




The trial was initiated in September 2013 and was completed in February 2016.  The breakdown of PP 
and ITT subjects by treatment arm and treatment center can be found in Supplemental Table 1.  164 
subjects were screened for eligibility, and 100 subjects were randomized. 19 subjects withdrew consent or 
were withdrawn during the course of the study including two subjects who were randomized in error.  81 
subjects completed the study.  4 subjects violated the exclusion criteria during the study, 5 subjects did not 
demonstrate a level of headache diary adherence sufficient to be included in the efficacy analysis and 16 
subjects received the partially active placebo condition (and thus were only assessed for safety).   Of the 
subjects  that completed, 49 were included in the PP analysis for efficacy, and 57 were included in the ITT 
analysis for efficacy (Figure 2).  Within the PP and the ITT groups, three and six subjects, respectively, 
exhibited more than 14 headache days during at least one treatment month.   We believe that some of these 
subjects were likely chronic migraineurs that went undetected during the baseline screening period
20, 21
.  In 
support of this hypothesis, a significant portion of subjects (15.2%) who entered the baseline screening 
process with a diagnosis of episodic migraine exhibited 15 or more monthly headaches during the baseline 
screening month.  Yet, as the possibility that CVS treatment may increase migraine frequency could not be 
ruled out a priori, these 6 subjects are included in the primary analysis to establish efficacy for the 
prevention of episodic migraine.  However, a sub-analysis that excludes these 6 subjects is provided as 
supplementary data.       
There were no significant differences in demographics or concomitant medication usage between the 
active and placebo groups (Table 1).  
Primary efficacy endpoints.  The reduction in monthly migraine days during the third treatment month 
relative to the pre-treatment baseline month served as the primary efficacy endpoint for the study and is 
detailed in Table 2, Figure 3 and Supplemental Table 2.  Statistically significant reductions in the number 
of migraine days in the PP active group were observed as early as the first treatment month (PP: -1.5 ± 0.8 
days, p = 0.0396; ITT: -1.3 ± 0.7, p = 0.0362), and monthly migraine days continued to steadily decrease 
12 
 
over the treatment period with a final reduction during the third treatment month of -3.8 ± 0.6 days (p < 
0.0001) and -3.5 ± 0.6 days (p < 0.0001) in the PP and ITT groups, respectively.  The placebo group 
exhibited a small but statistically significant reduction in migraine days during the third treatment month (-
1.1± 0.6 days, p = 0.048).  Notably, the primary endpoint evaluation revealed a therapeutic gain of 2.8 
fewer monthly migraine days in active arm subjects relative to placebo arm subjects after three months of 
CVS therapy (p = 0.012).  No effects of age, sex, race or concomitant medications were observed in the 
univariate analysis (Supplemental Figure 3). 
Secondary efficacy endpoints.  Secondary efficacy endpoints are detailed in Table 2, Figure 3 and 
Supplemental Table 2.  A trend for increased 50% responder rates in the active arm relative to the placebo 
arm existed in both the PP and the ITT analysis.  The lack of statistical significance for this effect was 
likely due to insufficient sampling for this binary statistical test given that the 50% responder rates in the 
placebo condition (31.6%) were significantly higher than originally anticipated (15%).  However, 
comparison of the percent-change in migraine days across the two PP groups (Table 2, Figure 3B) revealed 
that the response rate was significantly greater in active arm subjects (-47.1% ± 7.0%) than in placebo arm 
subjects (-14.9% ± 13.5%, p = 0.029).    
In addition to the reduction in migraine frequency, the efficacy of CVS treatment was also assessed by 
evaluating the reduction in subject-reported total monthly headache pain scores and the number of migraine 
abortive prescription medications taken.  Subjects in both the active arm and the placebo arm showed 
reductions in total monthly headache pain burden between the baseline and the third treatment month.  
However, group-wise comparison of the PP groups revealed that this effect size was significantly larger in 
the active arm subjects than in placebo arm subjects (therapeutic gain of -19.9%).  Similarly, subjects in 
both treatment arms took fewer migraine abortive prescription medications during the third treatment 
month compared to the pre-treatment baseline.  While placebo arm subjects also demonstrated a 
statistically significant reduction in this secondary endpoint, group-wise comparison of the reduction in 
migraine abortive prescription medications taken revealed that the effect was significantly larger in the 
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active arm than in the placebo arm in both the PP and the ITT cohorts (therapeutic gain of -23.4% and -
20.0%, respectively).  
Safety endpoints.  No serious or unexpected adverse events were reported during the trial in either the 
active or placebo groups.  Table 3 details all adverse events possibly related to device treatment reported 
during the study and the likelihood that each adverse event was related to treatment, as determined by the 
blinded clinicians.   
The side effects from the device were expected to be significantly attenuated in prevalence and severity 
compared to those reported from water and air irrigation
8
.  In line with this prediction, the cases of 
dizziness and/or nausea (also common symptoms in migraineurs) were limited (4 active, 2 placebo and 3 
partially active placebo cases, see Table 4). All cases were transient, and only two subjects listed 
dizziness/nausea as a reason for withdrawing consent; these consisted of one active subject and one placebo 
subject.  
Some ear discomfort from the device headset was also expected.  However, this adverse event was 
reported in less than 5% of study subjects (Table 3).  Furthermore, at the end of the three-month treatment 
period, 96.3% of subjects reported that the headset was comfortable enough to continue with treatment 
(Table 5).  One subject with pre-existing tinnitus felt that CVS treatment was potentially increasing tinnitus 
symptoms and withdrew consent.  However, that subject was diagnosed with a sinus infection eight days 
later, and symptoms returned to normal within 11 days of early termination. 
Although there are no reports in the literature or evidence from previous pilot studies using the device to 
suggest that CVS may disrupt normal vestibular function, the safety profile of longitudinal therapy using 
the device was further established by evaluating whether there was any deterioration in balance over the 
course of the study.  Balance was assessed using the Berg balance scale on treatment day one, the two- 
week follow-up visit and the final visit.  The Berg balance scale is a well-established diagnostic assessment 
for vestibular dysfunction and consists of 14 balance-related tasks.  No changes in balance were observed 
in any of the treatment groups over the course of the study (Table 4).  
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 We also sought to establish whether CVS treatment had any effect on mood or cognition.  A battery of 
standardized mood and cognitive tests was performed on treatment day one, the two-week follow-up visit 
and on the final visit.  Assessment of the baseline scores for the BDI-II and BAI revealed that very few 
subjects in our study exhibited baseline mood dysfunction.  Additionally, the baseline scores for all 
cognitive tests fell within expected ranges.  The performance-based cognitive tests showed significant 
changes within group over time, as would be expected due to practice effects; however, there was no 
compelling evidence of gains across measures by group, as seen by comparison of change scores in active 
versus placebo conditions.  Yet, while the study was inadequately powered to evaluate whether CVS 
treatment was efficacious in treating mood or cognitive dysfunction, neither active nor placebo treatment 
negatively impacted any measure of the mood or cognitive (Table 5) well-being, further demonstrating the 
safety of the device.   
Treatment adherence and device usability.   Treatment times and durations were recorded by the 
device.  Evaluation of these measures revealed that treatment adherence over the three months of treatment 
was excellent in both groups (86.3% ± 2.2%, n = 39 for active and 93.1% ± 1.1%, n = 37 for placebo).  
Three subjects were withdrawn from the study due to poor treatment/diary adherence.  31% of active arm 
subjects indicated that the treatment regimen was challenging to maintain, yet this subgroup still 
maintained an adherence rate of 79.7% ± 3.4%.  The remaining 69% of active arm subjects indicated that 
the time spent treating each day was either enjoyable or acceptable (Table 5).  
 Critical elements for adherence of any device prevention therapy are the ease of use and the subjective 
experience of using the device.  When surveyed, 90% (73/81) of subjects that completed the study reported 
that the device was easy to use at home, and 78% (63/81) indicated they had an overall positive experience 
with the device (Table 5).   
 
Blinding.  To assess whether subject blinding remained intact over the course of study, at the end of the 
three-month treatment period subjects were asked to guess their treatment allocation.  The results are 
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summarized in Figure 4.  In the placebo arm, 12 of 21 (57.1%) guessed that they received the placebo 
treatment, a rate of correct guessing that was no better than chance (compared to a hypothesized correct 
guessing rate of 50%, p = 0.639).  These results indicate that subjects in the placebo arm were adequately 
blinded to their allocation.  71.4% of active arm subjects did correctly guess their treatment allocation, a 
rate of correct guessing that was significantly better than chance (compared to a hypothesized correct 
guessing rate of 50%, p = 0.044).  While these results might suggest that active arm subjects were not 
adequately blinded, analysis of subject-provided reasons revealed that subjects based their allocation 
guesses primarily on perceived clinical efficacy rather than on palpable sensory experiences.  When asked 
for the reason behind their guess, 18 of 32 (56.3%) of subjects in the active arm who guessed active arm 
allocation specifically stated a clinical improvement as the reason for their guess.  Likewise, seven of ten 
(70.0%) of the active arm subjects who guessed that they had been allocated to the placebo arm provided a 
lack of clinical efficacy as a reason for their guess.  Eight of thirty-two (25.0%) active arm subjects who 
guessed active allocation and three of ten (30.0%) active arm subjects who guessed placebo arm allocation 
did not provide a reason for their guess.   Of the active arm subjects who did not provide a rationale for 
their guess, 6/8 (75.0%) of those who guessed active arm allocation did experience a significant reduction 
in monthly migraine days (-70.2% ± 10.0%) during the third treatment month relative to the pre-treatment 
baseline.  Of the other two subjects, one had no change in monthly migraine days and the other was diary 
non-compliant (and thus efficacy could not be accurately assessed).  Notably, only three subjects 
mentioned sensory experiences (i.e., warming and cooling of the ears) as a reason for guessing active 
allocation.  Of these three subjects, two also discussed clinical efficacy as a reason for their guess.  
To further explore whether the migraine prophylaxis from CVS therapy might be mediated by a placebo-
effect, we performed a secondary analysis of the change in migraine days over the course of the study, 
specifically focusing on PP subjects who guessed they had received active treatment.  If therapeutic gains 
in the number of monthly migraine days were indeed mediated by a placebo effect, a similar rate of clinical 
improvements would be expected for all subjects who guessed that they had received active treatment 
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regardless of their treatment allocation.  However, within PP subjects who guessed that they had been 
allocated to the active arm, subjects who had received active treatment showed significantly greater 
reductions in monthly migraine days compared to those subjects who had received a placebo treatment 
(either inactive placebo or partially active placebo; Figure 4, main effect of treatment: : F(1,11) =  12.43; p = 
0.005 , and treatment by time interaction: F(3,33) =  2.01; p = 0.131.   Finally, to rule out the possibility that 
sensory stimuli may have biased subjects by eliciting preconceived notions, we performed a final analysis 
of the PP data which excluded all subjects who mentioned any kind of sensory experience as a reason for 
their allocation guess (e.g., temperature change in the ears, the visual display on the touch screen, the lack 
of experience of expected side-effects).  In this analysis which excluded two active arm and three placebo 
arm PP subjects, active treatment still provided significant therapeutic gains over placebo treatment 
(Supplemental Figure 4, main effect of treatment: F(1,14) =  7.94; p = 0.014, and treatment by time 
interaction: F(3,42) =  2.08; p = 0.117, linear mixed model). 
IV. DISCUSSION 
 This randomized, double-blinded, placebo-controlled trial demonstrates that treatment with the solid-
state CVS device provides an efficacious and well-tolerated adjuvant prophylactic therapy for episodic 
migraine. Active arm subjects, who were already receiving standard-of-care therapies, exhibited 
significantly fewer monthly migraine days as early as the first treatment month, and the number of monthly 
migraine days decreased steadily over the course of treatment with a final reduction of -3.8 migraine days 
during the final treatment month, representing a therapeutic gain of -2.7 monthly migraine days.  
Furthermore, the lack of asymptote in the percent change of monthly migraine days over time (Figure 3A, 
C) suggests the possibility that patients may continue to improve further over longer treatment periods.  To 
reproduce the reported findings described herein and assess the therapeutic potential for longer treatment 
periods, a second research clinical trial (clinicaltrials.gov: NCT02991430) has been initiated.  This 
replication study will also seek to establish whether CVS therapy provides durable migraine prophylaxis. 
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In the current study, three months of active CVS treatment significantly reduced the total monthly 
headache pain scores in patients already receiving standard-of-care therapies by 48.1% and the acute anti-
migraine prescription medication intake by 51.3% in the PP group.  While the placebo group also exhibited 
statistically significant reductions within these domains, active treatment provided therapeutic gains  20% 
for both secondary outcome measures, indicating that CVS is likely to significantly improve the health 
economics of treating episodic migraine.  Although there was not a statistically significant difference in the 
50% responder rate between the active and placebo groups, an effect likely due to insufficient sampling, a 
UHVSRQVHUDWHZDVREVHUYHGLQDVXEVWDQWLal percentage of active arm subjects (57% of PP and 53% 
of ITT subjects).  Additionally, group-wise comparisons of the PP groups revealed that active arm subjects 
had greater percent-change in monthly migraine days after three months of treatment than placebo arm 
subjects (therapeutic gain of -32.2%).   Notably, the efficacy of CVS for reducing migraine burden was not 
affected by concomitant drug use (Supplemental Figure 3D), indicating that CVS can be successfully used 
as an adjuvant therapy and may provide migraine prophylaxis through a parallel mechanism of action. 
Side effects for CVS treatment were expected to be similar to those associated with irrigation-based 
diagnostic calorics (i.e., dizziness/nausea) though less severe owing to the reduced slew rate and less 
extreme temperature dynamic range provided by the programmed device
8
. Indeed, temporary 
dizziness/nausea occurred in only four active-arm subjects (8.1%), for whom the effects were considered to 
be mild in three and moderate in one.  Notably, in only one subject were these effects considered to be of 
probable relation to the device (Table 3).    
 The lack of change in balance scores or falls for any treatment groups over the course of the study (Table 
4) confirmed that longitudinal CVS treatment over three months has no negative sequela on vestibular 
function and further validated the safety of CVS therapy.  Our inclusion criteria mandated that subjects 
exhibit no evidence of pre-existing balance disorders.  As such, it is unclear whether patients with 
comorbid vestibular dysfunction would experience similar rates of migraine prevention efficacy, safety and 
tolerability, as those observed in this trial.   
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The lack of negative outcomes on measures of mood and cognition further highlight the safety of CVS 
therapy.  Although mood and cognitive measures were originally intended to serve as a secondary efficacy 
endpoint, evaluation of baseline data indicated that there was little mood or cognitive dysfunction in our 
randomized study cohort.  Though migraine does exhibit significant comorbidity with psychiatric 
disorders
14
, our exclusion of subjects with histories of either unstable mood or anxiety disorders or 
diagnoses of neurological disorders besides migraine as well as our focus on episodic rather than chronic 
migraineurs likely limited the number of subjects with whom the therapeutic potential of CVS for mood 
and/or cognitive dysfunction could be assessed
36
.  Yet, notably, the lack of negative effects of CVS 
treatment on any measure of mood or cognition as well as the absence of any AEs relating to fatigue and/or 
somnolence further exemplify the safety and tolerability of CVS therapy. 
 The active CVS group demonstrated an excellent overall rate of treatment adherence (86.3% ± 2.2%).  
This finding is especially noteworthy when one considers that CVS therapy requires subjects to suspend 
mobile activities and lie supine for the duration of treatment (totaling, in this study, 36 minutes per day).  
Future studies will be required to determine whether high CVS treatment adherence may relate to either an 
immediate reduction in migraine frequency or to a positive subjective experience with using the device, 
both of which were frequently reported in this study (Table 5).  Furthermore, the ability of the CVS device 
to record treatments provides a unique opportunity to evaluate whether and how clinical efficacy relates to 
treatment adherence.  In addition to using standard methods of evaluating treatment efficacy across PP and 
ITT groups, inferential analysis will be performed in the next research clinical trial to determine whether 
the rate of clinical improvement relates to treatment adherence. 
The use of inactive treatment control arms in randomized controlled trials is viewed as being fundamental 
to establishing clinical efficacy of both drugs and devices.  Whereas active and placebo pills can be made to 
look identical, non-invasive neuromodulation devices are likely to generate palpable sensory stimuli in 
active mode and thus often present significant challenges for maintaining treatment blinding in active arm 
subjects.  While the rate of correct allocation guesses in the active treatment arm in our study (71.4%) 
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might appear to indicate that active arm subjects had become aware of their treatment allocation, a careful 
analysis of subject-provided reasons for their allocation guesses revealed that subjects primarily based their 
guesses on their perceived rate of clinical improvement (Figure 4).   Indeed, only 3 of the 49 active arm 
subjects mentioned experiencing the warming/cooling sensations as reason for their allocation guess (i.e., 
the sensory experience that could have un-blinded them to their treatment condition). These results suggest 
that subjects did not attribute temperature changes in the ear canal as being a mechanism for 
neurostimulation, an observation that is unsurprising given the public focus on electrical stimulation for 
medical therapies, the absence of CVS within current treatment practice and the limited exposure to caloric 
vestibular stimulation that subjects with normal vestibular function are likely to have experienced prior to 
study participation.   
Ideally, placebo devices should deliver a sub-therapeutic stimulus so as to directly mimic the active 
device
37, 38
.  However, this approach presumes that a sub-threshold stimulus is well characterized, which 
may not be the case for a new experimental device.  The initial placebo waveform in this study was 
designed to provide a subthreshold stimulus by taking both ear pieces from room temperature to 3%e&DQG
maintaining that temperature for the remainder of treatment.  However, the presence of dizziness/nausea 
related to device treatment in three subjects provided clear evidence that the waveform produced 
substantive caloric vestibular stimulation.  As such, the placebo condition was modified so that no power 
was delivered to the heating and cooling components in the headset.  To ensure the integrity of results,  
both placebo conditions in this study produced a similar range of sensory experiences so as to produce an 
effective blind.  Both active and placebo subjects went through the same choreography for treatment (i.e., 
starting the protocol using the touchscreen and lying back on a wedge pillow for treatment, cleaning and 
storing the device), felt pressure in the ear canals as well as an initial cooling sensation from initial headset 
placement and heard both the faint whirring noise produced by the cooling fans and the tones produced at 
the start and stop of treatment.  Notably, a sub-analysis of PP subjects excluding all subjects that mentioned 
any kind of sensory experience during treatment as reason for their allocation guess (Supplemental Figure 
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4) showed clear separation between placebo and active arms, suggesting that differences in palpable 
sensory stimuli between the two treatment conditions were unlikely to account for prevention of episodic 
migraine.  Furthermore, if the inactive placebo was insufficient to produce a believable blind, one might 
expect treatment adherence to be significantly attenuated within this treatment group.  However, inactive 
placebo subjects demonstrated excellent overall treatment adherence (93.1% ± 1.1%).  Together, these data 
indicate that subjects remained effectively blinded to treatment allocation over the course of the study. 
To further explore whether efficacy of CVS therapy may have been driven by a placebo effect, we 
examined the change in monthly migraine days specifically in subjects that guessed that they had received 
active allocation (Figure 4) and found clear separation between the active and placebo arm subjects. The 
results from this sub-analysis may underestimate the therapeutic gain, particularly in the third treatment 
month for two reasons.  First, the placebo group in this analysis combined data from the partially active 
placebo and the inactive placebo groups.  Given the evidence for some vestibular stimulation in the 
partially active placebo condition, there may have been a substantive degree of vestibular stimulation which 
could have provided partial efficacy for migraine prevention.  Second, the timing of the allocation guess 
during the final assessment and the finding that subjects primarily based their allocation guesses on 
perceived clinical efficacy may bias this sub-analysis towards subjects that experienced stochastic 
reductions in monthly migraine days during the third treatment month.  The active group in this sub-
analysis showed a relatively stable reduction in migraine days during treatment months two and three, but 
the placebo group demonstrated additional reductions during the third treatment month suggesting that this 
biasing effect may be more likely to affect the placebo group. Yet, despite these confounding factors which 
are likely to reduce therapeutic effect size, the reduction in monthly migraine days for subjects guessing 
active arm allocation was significantly greater in subjects receiving active treatment compared to the 
placebo, thus strongly suggesting that device efficacy was derived from vestibular stimulation rather than 
from placebo-effect mediated phenomenon.  
21 
 
While the mechanism of action for CVS-mediated migraine prevention remains unknown, we 
hypothesize that our effects are mediated by neuromodulation of relevant brainstem centers. While 
migraine is often associated with vascular flow abnormalities, neuroimaging studies provide evidence that 
migraine is a neurological disorder involving brainstem dysfunction
9-11
.  The time-varying CVS waveforms 
used in this study (Figure 1B) provide substantive vestibular stimulation and induce oscillations in 
cerebrovascular dynamics that are consistent with brainstem neuromodulation
8
.  Additionally, vestibular 
nuclei innervate numerous brainstem regions implicated in migraine
14-16
 (see Figure 2C).  Future studies 
using neuroimaging approaches may help elucidate mechanism by identifying both the neural circuits and 
temporal dynamics of activation elicited by this CVS protocol. 
 The primary limitation of this study arose from the change in the placebo protocol during the course of 
this study.  Once subjects presented with dizziness/nausea in association with the initial placebo condition, 
it became apparent that the supposedly inactive waveform elicited substantive vestibular stimulation and 
thus was unlikely to provide a good null stimulation comparator for the active arm subjects. The revised 
protocol was approved by all IRBs, and the FDA was made aware of the protocol change; and this 
modification split the ÒplaceboÓ condition into two distinct groups.  The decrease in the placebo sample 
size reduced statistical power for observing statistically significant primary and secondary endpoints. Yet, 
importantly, the primary endpoint for both the PP and ITT groups was still statistically significant even 
with the change in protocol.  Furthermore, when the two placebo conditions are pooled, active treatment 
still shows statistically significant therapeutic gains over the combined placebo conditions (-2.3 and -2.0 
monthly migraine days for the PP and ITT groups, respectively; see Supplemental Figure 2).  Finally, the 
primary and secondary outcome measures in our study depended on adherence to daily headache diaries 
throughout the course of the study.  Thus, as with all diary-based studies, the study was also limited in so 
far as it was not able to assess efficacy in subjects that withdrew from the study or demonstrated significant 
non-adherence to the daily electronic headache diary.  Rather than imputing data for these subjects, use of a 
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modified ITT group in this study provides accurate results clarifying the expected rates of efficacy across 
of spectrum of treatment adherence. 
This pivotal study evaluated safety and efficacy in a relatively homogenous sample (episodic migraineurs 
between the ages of 18-65), however, CVS therapy may also provide a much-needed therapeutic option for 
adolescent migraineurs.  Parents often resist the idea of their children taking daily medication given the 
side-effect profiles and marginal therapeutic gains of the available prophylactics
39
.  However, preventative 
strategies not only improve quality of life, but may also decrease the longitudinal progression to chronic 
disease states in pediatric migraineurs
40, 41
.  Although migraine symptoms differ slightly between 
adolescent and adult populations
42
, the underlying migraine pathophysiology is presumed to be the same
43
.  
The long history demonstrating the safety of irrigation-based CVS in pediatric populations
44, 45
 suggest that 
pediatric migraineurs would experience a similar safety/tolerability profile as reported herein.  
Furthermore, the early maturation of the vestibular system and brainstem structures suggests that pediatric 
migraineurs may experience similar rates of efficacy.  Another natural extension of this work would be to 
evaluate efficacy for preventing chronic migraines and will be the focus of future studies.   Furthermore, 
owing to the non-chemical mechanisms of action for therapy, the therapeutic potential for CVS therapy to 
help wean subjects with medication overuse headache off acute abortive medications could also be 
explored in future studies. 
V. CONCLUSION 
 
The results from this randomized, double-blinded, placebo-controlled trial demonstrate that CVS 
treatment with a novel solid-state device significantly reduces the number of migraine days per month as 
well as the subjective headache pain scores and the need for migraine abortive prescription medications.  
Treatment can be administered in the home-setting with no technical expertise and modest training.  
Subjects demonstrated high rates of treatment adherence and also reported subjectively positive 
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experiences with using the device.  Together, these results indicate that CVS therapy addresses the existing 
need for new prophylactic therapies for episodic migraine.  This approach appears to be both efficacious 
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Figure 1.  CVS treatment. (A) Schematic of a patient undergoing treatment while wearing the 
CVS headset and lying on an incline wedge pillow.  (B) Example of target and actual thermal 
profiles of the saw-tooth time-varying thermal waveform used for active arm subjects in this 
study.  (C) The mechanism of action of CVS and projections of the vestibular nuclei to brain 
regions implicated in migraine.  The action potential firing rates of the vestibulochoclear nerves 
are increased by the warming of the left ear and decreased by cooling of the right ear.  These 
nerves innervate the vestibular nuclei in the brainstem which send both direct and indirect 
excitatory afferents to a number of brainstem nuclei implicated in migraine pathology.  The 
vestibular nuclei also show extensive polysynaptic connectivity with numerous structures in the 
midbrain and forebrain affected in migraine pathology.  Orientation of the brain has been turned 
%eWRVKRZFRQQHFWLYLW\LQDVDJLWWDOFURVV-section.
 Figure 2. Study design. 
 Figure 3.  Prophylactic efficacy of CVS for episodic migraine.  (A) Change in migraine days 
over the course of treatment relative to baseline (BL) in the per-protocol groups.  Active versus 
placebo: main effect of treatment: F(1,18) =  12.10; p = 0.003, and treatment by time interaction: 
F(3,54) =  5.21; p = 0.003, linear mixed model.  (B) Distribution of the percent-change in monthly 
migraine days between the third treatment month (Mo. 3) and BL for the per-protocol analysis.  
(C) Change in migraine days over the course of treatment relative to baseline (BL) in the 
intention-to-treat (ITT) groups.  Active versus placebo, main effect of treatment: F(1,18) =  10.62; 
p = 0.004, and treatment by time interaction: F(3,54) =  3.81; p = 0.015, linear mixed model.  (D) 
Distribution summary for the percent-change in monthly migraine days between Mo. 3 and BL 
for the ITT analysis. Summaries of the change scores for (E) the total monthly headache pain and 
(F) the monthly use of prescription (Rx) migraine abortive drugs between Mo.3 and BL.  Data 
for all panels are presented as the mean ± standard error of the mean. * p < 0.05.  
 
Figure 4.  Assessment of treatment blinding.  (A) Summary showing the distribution of 
subjects correctly guessing treatment allocation at the end of the study.  Summaries of the 
subject-provided reasons for guessing (B) active arm allocation or (C) placebo arm allocation 
gathered from hand-written answers provided by subjects on an end-of study questionnaire.  
Summaries showing the distribution of subject-specified reasons and inferred reasons based on 
the change in migraine days between the third treatment month pre-treatment baseline and for 
guessing (D) active arm allocation and (E) placebo arm allocation. (F) Migraine days over the 
course of treatment in the per-protocol (PP) groups for subjects that guessed active allocation. 
(G) Change in migraine days over the course of treatment relative to baseline (BL) in the per-
protocol (PP) groups for subjects that guessed active allocation.  Active versus placebo F(1,11) =  
12.43; p = 0.005, and treatment by time interaction: F(3,33) =  2.01; p = 0.131, linear mixed 





























Table 1.  Patient demographics. 
    
!! Per protocol (all) Intention-to-treat (all) 
!! Active Placebo Active Placebo 
n  30 18 39 19 
Age (years) 45.4 ± 1.9 39.3 ± 3.2 44.4 ± 1.7 39.6 ± 3.1 
Disease duration (years) 25.7 ± 2.4 20.6 ± 2.8 25.5 ± 2.0 21.2 ± 2.7 
Sex         
  Male, n (%) 4 (13.3%) 2 (11.1%) 5 (12.8%) 2 (10.5%) 
  Female, n (%) 26 (86.7%) 16 (88.9%) 34 (87.2%) 17 (89.5%) 
Education (years) 16.1 ± 0.5 15.5 ± 0.6 15.5 ± 0.6 15.5 ± 0.6 
Migraine with occasional aura, n (%) 7 (23.3%) 8 (44.4%) 8 (20.5 %) 8 (42.1%) 
Exclusively migraine without aura, n (%) 23 (76.7%) 10 (55.6%) 21 (79.5%) 11 (57.9%) 
Concomittant medications         
  Antiepileptics (AEDs) 5 (17.9%) 2 (11.1%) 6 (15.4%) 2 (10.5%) 
  Antihistamines 7 (25.0%) 6 (33.3%) 7 (17.9%) 7 (36.8%) 
  Antinausea medications 3 (10.7%) 1 (5.6%) 4 (10.3%) 1 (5.3%) 
  ȕEORFNHUVDQWLK\SHUWHQVLYHV 4 (14.3%) 6 (33.3%) 5 (12.8%) 7 (36.8%) 
  NA or DA drugs 8 (28.6%) 4 (22.2%) 9 (23.1%) 4 (21.1%) 
  SERT inhibitors 8 (28.6%) 6 (33.3%) 9 (23.1%) 7 (36.8%) 
  Hormones (birth control, etc.) 8 (28.6%) 6 (33.3%) 8 (20.5%) 7 (36.8%) 
!!         


























Table 2. Primary and secondary outcomes. 
    
 
Per protocol Intention-to-treat 
  Active Placebo Active Placebo 
    n 30 19 38 19 
Migraine days (baseline compared to third month of treatment) 
  Migraine days (baseline) 7.7 ± 0.5 6.9 ± 0.7 7.7 ± 0.4 6.9 ± 0.7 
  Migraine days (third treatment month) 3.8 ± 0.5 5.8 ± 0.9 4.2 ± 0.5 5.8 ± 0.9 
  Change in migraine days  -3.8 ± 0.6 -1.1 ± 0.6 -3.5 ± 0.6 -1.1 ± 0.6 
    95% confidence interval -5.1 to -2.5 -2.4 to 0.3 -4.7 to -2.3 -2.4 to 0.3 
    p < 0.0001 * 0.048 * < 0.0001 * 0.048 * 
  Difference between groups (migraine days) -2.8   -2.5   
     95% confidence interval -0.9 to -4.7 
 
-0.6 to -4.4 
     Comparison between groups, p 0.0119 *   0.0205 *   
     Percentage of responders (reduction in monthly migraine days from baseline to third treatment month) 
  5HVSRQGHUVUHGXFWLRQ 17 (56.7.1%) 6 (31.6%) 20 (52.6%) 6 (31.6%) 
    Comparison between the 2 groups, p 0.0864   0.1325   









    Comparison between the 2 groups, p 0.0288 *   0.0534   
     Total monthly headache pain scores (baseline compared to third treatment month) 
  Total pain baseline month 45.7 ± 3.5 36.4 ± 3.9 44.7 ± 3.1 36.4 ± 3.9 
  Total pain third treatment month 23.7 ± 2.8 26.1 ± 3.3 25.4 ± 2.5 26.1 ± 3.3 
  Change in total pain  -22.0 ± 3.9 -10.3 ± 3.4 -19.3 ± 3.6 -10.3 ± 3.4 
    95% confidence interval -30.0 to -14.0 -17.5 to -3.1 -26.4 to -11.9 -17.5 to -3.1 
    p < 0.0001 * 0.0073 * < 0.0001 * 0.0073 * 
    Difference between groups (change in total pain) -11.7   -9.0   
       95% confidence interval -23.0 to -0.3 
 
-20.4 to 2.5 
     Comparison between groups, p 0.0437 *   0.1218   
     Acute anti-migraine prescription drug intake (baseline compared to third treatment month) 
  n (subjects with current antimigraine prescriptions) 26 17 33 17 
  Acute anti-migraine drugs intake (baseline) 7.6 ± 0.8 6.1 ± 1.6 7.3 ± 0.7 6.1 ± 1.6 
  Acute anti-migraine drug intake third month 3.7 ± 0.6 4.4 ± 1.4 3.8 ± 0.6 4.4 ± 1.4 
  Change in anti-migraine drug intake -3.9 ± 0.6 -1.7 ± 0.8 -3.5 ± 0.6 -1.8 ± 0.8 
    Change (third month - baseline), p < 0.0001 * 0.0450 * < 0.0001 * 0.0450 * 
    Difference between groups (anti-migraine drugs) -2.2   -1.7   
       95% confidence interval -4.2 to -0.1 
 
-3.8 to 0.3 
     Comparison between groups, p 0.0375*   0.1001   
     * p < 0.05. 




Table 3.  Adverse Events with possible relationship to device use. 
 
  Active Placebo 
Partially active 
placebo 
Randomized subjects 49 31 20 
Serious adverse events 0 0 0 
Unexpected adverse events 0 0 0 
Nausea and/or dizziness 5 2 3 
  Device relationship PoR (4), PrR (1) UR (1), PoR (1) R (2), PrR (1) 
Ear discomfort, itch, irritation, pruritus  2 1 1 
  Device relationship PoR (1), PrR (1) PoR (1) R (1) 
Tinnitus/buzzing 2 2 0 
  Device relationship PoR (1), PrR (1) PoR (2)   
Neck pain exacerbation 2 0 0 
  Device relationship UR (1), PoR (1) 
  
Increased migraines/headaches 3 0 1 
  Device relationship UR (2), PrR (1)   PoR (1) 
Blood pressure change during treatment 2 0 0 
  Device relationship UR (1), PoR (1) 
  
Eye twitching 0 1 0 
  Device relationship   PoR (1)   
Blurred vision 0 0 1 
  Device relationship 
  
UR (1) 
    
Abbreviations: UR (unlikely related), PoR (possibly related), PrR (probably related), R (related) 
Additionally, 1 patient (placebo) experienced the following adverse events deemed unlikely to be related to use 
of the device: ache in cheek, bad taste on tongue, blurred vision, itchy skin, jaw slipped out of alignment, 
menopausal symptoms, optical flashing and tingling left arm/wrist as well as right leg. 
1 subject (partially active placebo) experienced short-term memory loss deemed unlikely related. 

















 Table 4.  Safety measures 
      
  Per-protocol Intention-to-treat 
  Active Placebo 
Partially 
active 




n  34 20 14 40 22 17 
Mood and cognition assessment measures   
  Beck Depression Index 
      
    Baseline score 3.6 ± 1.1 4.2 ± 1.4 5.6 ± 1.4 4.0 ± 1.2 4.0 ± 1.3 5.5 ± 1.2 
    Change from baseline to third month -0.5 ± 0.4 -1.0 ± 0.7 -1.1 ± 1.7 -0.7 ± 0.4 -0.9 ± 0.7 -0.9 ± 1.4 
    p,(baseline vs. third month of treatment) 0.205 0.180 0.513 0.101 0.018 0.509 
   p, change scores (active vs. placebo) 0.499 0.583 
 
0.467 0.766 
  Beck Anxiety Index             
    Baseline score 3.9 ± 0.9 4.8 ± 1.3 5.2 ± 0.9 4.1 ± 0.7 4.6 ± 1.2 5.2 ± 0.9 
    Change from baseline to third month -0.3 ± 0.5 -1.5 ± 0.7 -0.6± 0.9 -0.4 ± 0.5 -1.4 ± 0.7 -0.8 ± 0.7 
    p,(baseline vs. third month of treatment) 0.521 0.057 0.516 0.467 0.058 0.278 
   p, change scores (active vs. placebo) 0.179 0.796   0.383 0.318 
Digit Symbol Coding 
      
    Baseline score 71.8 ± 3.5 74.0 ± 3.8 77.2 ± 4.4 71.0 ± 3.2 73.5 ± 3.7 78.7 ± 3.8 
    Change from baseline to third month 7.2 ± 2.3 5.0 ± 1.9 7.9 ± 3.5 7.1 ± 1.9 5.0 ± 1.9 7.4 ± 2.9 
    p,(baseline vs. third month of treatment) 0.003 * 0.018 * 0.042 * 0.001 * 0.014 * 0.022 * 
   p, change scores (active vs. placebo) 0.606 0.679 
 
0.353 0.998 
Trail Making Test A (seconds to comple)             
    Baseline score 28.7 ± 1.7 27.4 ± 1.7 26.1 ± 1.9 28.7 ± 1.5 27.3 ± 1.6 24.7 ± 1.8 
    Change from baseline to third month -6.5 ± 1.3 -5.9 ± 1.1 -3.6 ± 1.7 -6.3 ± 1.2 -5.7 ± 1.1 -2.9 ± 1.5 
    p,(baseline vs. third month of treatment) < 0.0001 * < 0.0001 * 0.060 < 0.0001 * < 0.0001 * 0.068 
   p, change scores (active vs. placebo) 0.264 0.826   0.352 0.328 
Trail Making Test B (seconds to complete) 
      
    Baseline score 73.5 ± 10.1 56.4 ± 4.2 55.2 ± 5.2 75.9 ± 9.1 56.3 ± 4.0 51.5 ± 4.8 
    Change from baseline to third month -24.0 ± 7.0 -10.1± 3.5 -5.3± 5.4 -24.1 ± 6.2 -9.5 ± 3.4 -1 ± 5.5 
    p,(baseline vs. third month of treatment) 0.002 * 0.010 * 0.343 0.0004 * 0.011 * 0.8591 
   p, change scores (active vs. placebo) 0.738 0.333 
 
0.211 0.150 
Controlled Oral Word Association              
    Baseline score 40.2 ± 2.0 35.6 ± 2.5 37.4 ± 3.4 40.4 ± 1.8 35.1 ± 2.5 38.3± 2.9 
    Change from baseline to third month 7.1 ± 1.5 4.2 ± 1.4 5.9 ± 2.4 6.2 ± 1.4 4.3 ± 1.4 4.7 ± 2.0 
    p,(baseline vs. third month of treatment) < 0.0001 * 0.009 * 0.027 * 0.0001 * 0.005 * 0.036 * 
   p, change scores (active vs. placebo) 0.167 0.161   0.329 0.039* 
Everyday Cognition - 20  
      
    Baseline score 5.7 ± 1.1 8.1 ± 1.9 12.9 ± 2.7 5.6 ± 1.0 7.8 ± 1.9 12.0 ± 2.3 
    Change from baseline to third month -0.2 ± 0.8 0.1 ± 1.7 -3.1 ± 1.5 0.7 ± 0.8 0.1 ± 1.6 -2.5 ± 1.3 
    p,(baseline vs. third month of treatment) 0.817 0.954 0.056 0.390 0.977 0.069 
   p, change scores (active vs. placebo) 0.866 0.057 
 
0.307 0.112 
Short term memory test (faces)             
    Baseline score 48.9 ± 1.0 48.5 ± 1.2 47.9 ± 1.6 48.1 ± 1.0 48.5 ± 1.1 48.7 ± 1.5 
    Change from baseline to third month -1.5 ± 1.0 -1.6 ± 1.6 1.3 ± 1.6 -1.0 ± 1.0 -1.9 ± 1.5 1.0 ± 1.5 
    p,(baseline vs. third month of treatment) 0.203 0.436 0.515 0.311 0.241 0.520 
   p, change scores (active vs. placebo) 0.977 0.135   0.603 0.681 
Long term memory test (faces) 
      
    Baseline score 39.1 ± 0.9 38.6 ± 1.1 41.1 ± 1.4 38.9 ± 0.8 39.1 ± 1.2 40.7 ± 1.2 
   p, (active vs. placebo) 0.753 0.213 
 
0.867 0.218 






   
Berg Balance scores             
    n 42 22 17 
   
    Baseline score 55.9 ±  0.1 56.0 ±  0.0 55.4 ±  0.4       
    Change from baseline to third month 0.0 ±  0.0 0.0 ±  0.0 0.3 ±  0.4 
   
    p,(baseline vs. third month of treatment) * 0.500 1.000 0.750       
Berg balance scores of 41-56 indicate low risk of fall, 21-40 indicate medium risk of fall and 0-20 indicate high risk of fall.             * p < 

































 Table 5.  Device usability survey responses at the end of 3 month treatment period. 
  Active Placebo 
Partially active 
placebo 
n 42 22 17 
Did you  find the headset to be comfortable enough to continue with your treatments? 
      Yes 42 (100.0%) 20 (90.1%) 16 (94.1 %) 
      No 0 (0.0%) 2 (9.1%) 1 (5.9%) 
Did you  find that the device is easy to use at home? † 
      Yes 37 (88.1 %) 21 (95.5%) 15 (88.%) 
      No opinion 0 (0.0%) 1 (4.5%) 0 (0.0%) 
      It was not easy, but I kept doing it. 5 (11.9%) 0 (0.0%) 2 (11.8%) 
      No 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Was the amount of time you spent treating per day 
      Enjoyable 8 (19.0%) 7 (31.8%) 3 (17.6%) 
      Acceptable 19 (45.2%) 14 (63.6%) 12 (70.6%) 
      Circled both Enjoyable and Acceptable 2 (4.8%) 0 (0.0%) 1 (5.9%) 
      No opinion 0 (0.0%) 0 (0.0%) 0 (0.0%) 
      Challenging to maintain 13 (31.0%) 1 (4.5%) 1 (5.9%) 
      Impossible to maintain 0 (0.0%) 0 (0.0%) 0 (0.0%) 
How would you rate your overall exeperience? 
      Very positive 18 (42.8%) 9 (40.9%) 8 (47.0%) 
      Somewhat positive 14 (33.3%) 10 (45.5%) 4 (23.5%) 
      No opinion 6 (14.3%) 1 (4.5%) 4 (23.5%) 
      Somewhat negative 4 (9.5%) 2 (9.1%) 1 (5.9%) 
      Very negative 0 (0.0%) 0 (0.0%) 0 (0.0%) 
    
† Of the 7 patients that indicated that the device was not easy to use at home, 4 active arm patients and 1 partially 
active placebo arm patient also indicated the time spent treating per day was challenging to maintain. 
Data are presented as n (%). 
    
  
 
Supplemental Table 1. Patient distributions. 





 (1) Naval Medical Center 2 (2) 0 (0) 2 (4) PP   
       San Diego, CA. USA. 2 (2) 0 (0) 2 (4) ITT   
  3 0 1 w.d. 
(2) Duke Pain Medicine 1 (1) 1 (1) 1 (1) PP   
       Durham, NC. USA. 2 (2) 1 (1) 1 (1) ITT   
 0 0 
1 w.d. 
(3) The National Migraine Centre 7 (7) 3 (3) 5 (5) PP   
      London, England 7 (7) 3 (3) 6 (6) ITT   
  2 1 0 w.d. 
(4) Michigan Head Pain & Neurological Institute 6 (6) 4 (4) 2 (2) PP   
       Ann Arbor, MI. USA. 8 (9) 4 (4) 3 (3) ITT   
 2 1 1 w.d. 
(5) Carolina Headache Institute 6 (8) 6 (7) 2 (2) PP   
      Chapel Hill, NC. USA. 7 (9) 6 (7) 2 (2) ITT   
  1 2 0 w.d. 
(6) Headache Wellness Center 6 (6) 4 (4) 0 (0) PP   
       Greensboro, NC. USA. 8 (9) 4 (4) 0 (0) ITT   
 0 4 0 w.d. 
Total 28 (30) 18 (19) 12 (14) PP   
  34 (39) 18 (19) 14 (16) ITT   
  8 8 3 w.d. 
Abbreviations: Per protocol (PP), Intention-to-treat (ITT), withdrew consent during treatment period (w.d.) 
† For PP and ITT n values: patients never exceeding 14 headache days during treatment months (all patients). 






























Supplemental Figure 1.  Thermal profiles of the placebo conditions.  Time course 
shows the target temperature (black) as well as the actual temperatures recorded by the 
thermistors located in the left ear piece (blue) and the right ear piece (red) in 




Supplemental Figure 2.  Prophylactic efficacy of CVS for episodic migraine comparing 
active treatment to all placebo conditions combined.  Change in migraine days over the 
course of treatment relative to the baseline (BL) period comparing subjects in the active arm to 
subjects in both the inactive placebo and the partially active placebo arms combined in (A) the 
per-protocol analysis and (B) the intention-to-treat analysis.  The change in monthly migraine 
days during the third treatment in the per-protocol group was -3.8 ± 0.6 days for active arm 
subjects and -1.5 ± 0.6 days for placebo arm subjects, representing a therapeutic gain of -2.3 
days, p = 0.0287 (Mann Whitney U-test).  The change in monthly migraine days during the third 
treatment in the intention-to-treat group was -3.5 ± 0.6 days for active arm subjects and -1.5 ± 
0.6 days for placebo arm subjects representing a therapeutic gain of -2.2 days, p = 0.0251 (Mann 




























Supplemental Table 2. Primary and secondary outcomes excluding subjects > 15 monthly headaches. 
 
Per protocol Intention-to-treat 
  Active Placebo Active Placebo 
    n 28 18 34 18 
Migraine days (baseline compared to third month of treatment) 
  Migraine days (baseline) 7.4 ± 0.5 6.7 ± 0.7 7.4 ± 0.4 6.7 ± 0.7 
  Migraine days (third month) 3.8 ± 0.5 5.8 ± 1.0 4.1 ± 0.5 5.8 ± 1.0 
  Change in migraine days (third month - baseline) -3.6 ± 0.7 -0.9 ± 0.7 -3.3 ± 0.6 -0.9 ± 0.7 
    95% confidence interval -5.0 to -2.3 -2.3 to 0.5 -4.6 to -1.7 -2.3 to 0.5 
    Change (third month - baseline), p < 0.0001 * 0.0786 < 0.0001 * 0.0786 
    Difference between groups (migraine days) 2.8   -2.4   
       95% confidence interval -0.8 to 4.7 
 
-0.4 to 4.3 
     Comparison between groups, p 0.0142 *   0.0246 *   
     Percentage of responders (reduction in monthly migraine days from baseline to third treatment month) 
  5HVSRQGHUVUHGXFWLRQ 16 (57.1%) 6 (33.3%) 18 (52.9%) 6 (33.3%) 
    Comparison between the 2 groups, p 0.1146   0.1772   










    Comparison between the 2 groups, p 0.0336 *   0.0677   
     Total monthly headache pain scores (baseline compared to third month of treatment) 
  Total pain baseline month 45.8 ± 3.7 35.7 ± 4.1 7.4 ± 0.5 7.4 ± 0.5 
  Total pain third month 24.5 ± 2.9 26.7 ± 3.5 7.4 ± 0.5 7.4 ± 0.5 
    p < 0.0001 * 0.015 * < 0.0001 * 0.015 * 
  Change from baseline to third month -21.3 ± 4.1 -8.9 ± 3.3 -18.7 ± 3.8 -8.9 ± 3.3 
    95% confidence interval 
-29.7 to -
12.9 -15.9 to -1.9 -29.0 to -6.0 -15.9 to -1.9 
    Comparison between the 2 groups, p 0.0382 *   0.0966   
     Acute anti-migraine prescription drug intake (baseline compared to third month of treatment) 
  n (subjects that took antimigraine prescription 
drugs) 24 16 29 16 
  Acute anti-migraine drugs intake (baseline) 7.3 ± 0.9 5.5 ± 1.6 7.3 ± 0.7 5.5 ± 1.6 
  Acute anti-migraine drug intake third month 3.6 ± 0.6 4.1 ± 1.5 3.9 ± 0.6 4.1 ± 1.5 
    p < 0.0001 * 0.0747 < 0.0001 * 0.0747 
  Change from run-in to third month -3.7 ± 0.7 -1.4 ± 0.8 -3.4 ± 0.6 -1.3 ± 0.8 
    95% confidence interval -5.1 to -2.4 -3.0 to -0.2 -5.1 to -2.4 -5.1 to -2.4 
    p 0.0195 * 
 
0.0464 * 
           
* p < 0.05. 



























































Supplemental Figure 3.  Treatment efficacy is not affected by age, sex, race or concomitant 
medications.  (A) The normalized percent-change in migraine days between baseline (BL) and the 
third month of treatment (mo. 3) plotted as a function of the age in years for each patient (p = 
0.253).  Scatter plots showing similar distributions of the percent-change in migraine days between 
baseline and the third month of treatment  (B) for female and male and (C) for Caucasian and 
African American subjects.  (D) Summary data showing treatment efficacy is not affected by 
concomitant medications.  Taking no prophylactics (n = 7), taking antiepileptic drugs (AED, n = 
8), not taking AED (n = 22), taking antihistamines (n = 7); not taking antihistamines (n = 23), 
taking anti-nausea medication (n = 3), not taking anti-nausea medication (n = 27WDNLQJȕEORFNHU
antihypertensive medication (n = 5 QRW WDNLQJ ȕ EORFNHU DQWLK\SHUWHQVLYH medication (n = 25), 
taking drugs affecting the norepinephrine (NE) and/or dopamine (DA) systems (n = 7), not taking 
drugs affecting the NE and/or DA systems (n = 23), taking a drug that blocks the plasma 
membrane serotonin transporter (SERT inhibitors, n = 7), not taking a SERT inhibitor (n = 23), 
taking hormonal birth control (n = 8), not taking hormonal birth control (n = 22).  All data for 
panels A-D were derived from the active arm per-protocol cohort.   Data in panels B-D are 





Supplemental Figure 4.  Treatment efficacy excluding all subjects who discussed sensory 
experiences related to device treatment as reason for allocation guess.  (A) Migraine days 
and (B) the change in migraine days over the course of treatment relative to the baseline month 
in the per-protocol groups excluding subjects that mentioned sensory experiences during device 
treatment as reason for their allocation guess.  For panel B, active versus placebo main effect of 
treatment: F(1,14) =  7.94; p = 0.014, and treatment by time interaction:  F(3,42) =  2.08; p = 0.117, 
linear mixed model 
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